Clinical Trial Update: Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a dasatinib-based combination in patients with refractory chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: UNKNOWN